Latest News for: telangiectasias

Edit

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Business Wire 16 Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq.
Edit

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia (Form 8-K) (Quince Therapeutics Inc)

Public Technologies 16 Jul 2025
Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia ... its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) ... About Ataxia-Telangiectasia.
Edit

Slipstream Co-Authors First Comprehensive Cost Study on Hereditary Hemorrhagic Telangiectasia in the American Journal of Hematology

Nasdaq Globe Newswire 10 Jul 2025
Slipstream is proud to announce its co-authorship of a groundbreaking study on Hereditary Hemorrhagic Telangiectasia (HHT) ... .
Edit

Slipstream Co-Authors First Comprehensive Cost Study on Hereditary Hemorrhagic Telangiectasia

The Eagle-Tribune 10 Jul 2025
... Telangiectasia (HHT), recently published in the American .
  • 1

Article Search

tools
×
×
×
×